Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REaCT-HER TIME: 6-months of HER2-targeted Therapy in Early-stage Breast Cancer
NCT04928261Phase 4Active, not recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of trastuzumab in breast cancer, sponsored by Ottawa Hospital Research Institute. Started Dec 2021; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04928261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928261.